Marit Sjo Lorentzen

Vermögen: 47 550 $ am 30.04.2024

56 Jahre

Health Technology

Consumer Services

Aktive Positionen von Marit Sjo Lorentzen

Unternehmen	Position	Beginn	Ende
ARCTICZYMES TECHNOLOGIES ASA	Geschäftsführer	-	-
ARCTICZYMES TECHNOLOGIES ASA	Direktor/Vorstandsmitglied	-	-
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Direktor/Vorstandsmitglied	-	-

University of Tromso

Undergraduate Degree

International

Norwegen

Operativ

Sektoral

Health Technology	3
Consumer Services	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Private Unternehmen	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology

Private Unternehmen

Health Technology